1-10 of 10
Cornelia Quadt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B143: HRO761, a first-in-class, clinical stage WRN inhibitor with potent preclinical anti-tumor activity in MSIhigh models

Free
Stephane Ferretti, Isabel Jaco, Andrea Decker, Christelle Hemmerlin, Clemens Scheufler, Cornelia Quadt, Dario Sterker, Elena Gavioli, Eloisa Jimenez Nunez, Ernesta Dammassa, Fanny Schaeffer, Genevieve Albrecht, Giorgia Clementi, Hansjoerg Martus, Jacques Hamon, Juergen Hinrichs, Laurent Laborde, Marion Dourdoigne, Michele Moschetta, Ramona Stump, Rita Andraos-Rey, Sarah Welly, Stephanie Barbe, Vincent Romanet, Markus Reschke, Ruben De Kanter, Michael Jensen, Henrik Moebitz, Marta Cortes Cros
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B143.
https://doi.org/10.1158/1535-7163.TARG-23-B143
Published: 01 December 2023
View article titled, Abstract B143: HRO761, a first-in-class, clinical stage WRN inhibitor with potent preclinical anti-tumor activity in MSIhigh models
Journal Articles

Abstract PR007: Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability

Free
Marta Cortes-Cros, Henrik Moebitz, Stephanie Barbe, Jutta Blank, Vincent Bordas, Giorgia Clementi, Ernesta Dammassa, Andrea Decker, Noemi Di Nanni, Ruben de Kanter, Marion Dourdoigne, Elena Gavioli, Stephane Ferretti, Marc Hattenberger, Christelle Hemmerlin, Jacques Hamon, Juergen Hinrichs, Isabel Jaco, Dragana Jankovic, Eloisa Jimenez Nunez, Yifang Li, Hans-Joerg Martus, Michele Moschetta, Cornelia Quadt, Markus Reschke, Vincent Romanet, Clemens Scheufler, Joseph Schoepfer, Ross Strang, Maxime Therier, Hans Voshol, Markus Wartmann, Sarah Welly, Monica Pham, Laurent Laborde
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): PR007.
https://doi.org/10.1158/1535-7163.TARG-23-PR007
Published: 01 December 2023
View article titled, Abstract PR007: Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability
Journal Articles

Abstract B188: A Phase l study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies.

Free
Yoshihito Kogure, Yasuhide Yamada, Hideo Saka, Chiyoe Kitagawa, Satoru Iwasa, Noboru Yamamoto, Takuji Aoki, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Ayako Mitsuma, Takashi Shibata, Yuichi Ando
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B188.
https://doi.org/10.1158/1535-7163.TARG-13-B188
Published: 01 November 2013
View article titled, Abstract B188: A Phase l study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies.
Journal Articles

Abstract A167: A phase I study of single-agent BEZ235 (SDS sachet), once- or twice-daily, in Japanese patients with advanced solid tumors.

Free
Koichiro Watanabe, Hironobu Minami, Satoshi Otsu, Yoshinori Hirashima, Ryotaro Morinaga, Kazuo Nishikawa, Yasushi Hisamatsu, Toru Mukohara, Naomi Kiyota, Naoko Chayahara, Masanori Toyoda, Yoshinori Imamura, Yutaka Fujiwara, Cornelia Quadt, Matthew Robson, Kazuto Natsume, Takuji Aoki, Kuniaki Shirao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A167.
https://doi.org/10.1158/1535-7163.TARG-13-A167
Published: 01 November 2013
View article titled, Abstract A167: A phase I study of single-agent BEZ235 (SDS sachet), once- or twice-daily, in Japanese patients with advanced solid tumors.
Journal Articles

Abstract B106: mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.

Free
Moshe Elkabets, Sadhna Vora, Dejan Juric, Natasha Morse, Mari Mino-Kenudson, Taru Muranen, Jessica Tao, Ana Bosch Campos, Jordi Rodon, Yasir H. Ibrahim, Violeta Serra, Vanessa Rodrik-Outmezguine, Saswati Hazra, Sharat Singh, Phillip Kim, Cornelia Quadt, Liu Manway, Alan Huang, Neal Rosen, Jeffrey A. Engelman, Maurizio Scaltriti, José Baselga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B106.
https://doi.org/10.1158/1535-7163.TARG-13-B106
Published: 01 November 2013
View article titled, Abstract B106: mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Journal Articles

The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth

Free
Edward B. Garon, Richard S. Finn, Habib Hamidi, Judy Dering, Sharon Pitts, Naeimeh Kamranpour, Amrita J. Desai, Wylie Hosmer, Susan Ide, Emin Avsar, Michael Rugaard Jensen, Cornelia Quadt, Manway Liu, Steven M. Dubinett, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 890–900.
https://doi.org/10.1158/1535-7163.MCT-12-0998
Published: 09 June 2013
View article titled, The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
Open the PDF for The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth in another window
Includes: Supplementary data
Journal Articles

Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer

Free
Zev A. Wainberg, Adrian Anghel, Amy M. Rogers, Amrita J. Desai, Ondrej Kalous, Dylan Conklin, Raul Ayala, Neil A. O'Brien, Cornelia Quadt, Mikhail Akimov, Dennis J. Slamon, Richard S. Finn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (4): 509–519.
https://doi.org/10.1158/1535-7163.MCT-12-0507
Published: 08 April 2013
View article titled, Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
Open the PDF for Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B159: Phase I dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.

Free
Toshihiko Doi, Yuichi Ando, Hideaki Bando, Takayuki Yoshino, Megumi Inada, Ayako Mitsuma, Cornelia Quadt, Matthew Robson, Atsushi Ohtsu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B159.
https://doi.org/10.1158/1535-7163.TARG-11-B159
Published: 12 November 2011
View article titled, Abstract B159: Phase I dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Journal Articles

Abstract C196: Co‐treatment with NVP‐BEZ235 and heat shock protein (hsp) 90 or pan‐deacetylase (DAC) inhibitor is synergistically active against non‐small cell lung cancer (NSCLC) cells with mutant RAS and LKB1

Free
Sunil Upadhyay, Warren C. Fiskus, Rekha Rao, Atul Joshi, Sanjay Koul, Ramesh Balusu, Uma Mudunuru, Kathleen M. Buckley, Cornelia Quadt, Peter Atadja, Carlos Garcia‐Echeverria, Kapil N. Bhalla
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C196.
https://doi.org/10.1158/1535-7163.TARG-09-C196
Published: 10 December 2009
View article titled, Abstract C196: Co‐treatment with NVP‐BEZ235 and heat shock protein (hsp) 90 or pan‐deacetylase (DAC) inhibitor is synergistically active against non‐small cell lung cancer (NSCLC) cells with mutant RAS and LKB1
Journal Articles

NVP-AUY922: A novel small molecule HSP90 inhibitor with potent in vivo antitumor efficacy

Free
Michael Rugaard Jensen, Joseph Schoepfer, Thomas Radimersky, Andrew Massey, Josef Brueggen, Alain Schweitzer, Ulrike Pfaar, Stephan Ruetz, Chantal Guy, Alan Buckler, Christian Schnell, Robert Cozens, Paul Brough, Martin Drysdale, Cornelia Quadt, Carlos Garcia-Echeverria, Patrick Chene
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B279.
Published: 01 November 2007
View article titled, NVP-AUY922: A novel small molecule HSP90 inhibitor with potent in vivo antitumor efficacy